Choroideremia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Choroideremia is a rare X-linked recessive genetic disorder characterized by progressive vision loss, primarily affecting males. It is caused by mutations in the CHM gene located at Xq21.2, responsible for producing the Rab escort protein-1 (REP-1). In affected males, the condition typically manifests as night blindness (nyctalopia) during their first or second decade. This is followed by a narrowing of the peripheral visual field, with a progression from ring-shaped blind spots (annular scotomas) to a more extensive visual field loss. Visual acuity impairment becomes noticeable by mid-adulthood. Over time, changes in the fundus (the back of the eye) are observed, initially showing pigmentary stippling and focal areas of choroid atrophy in the equatorial fundus. In the advanced stages, extensive degenerative changes occur in the retinal pigment epithelium (RPE), with only remnants of the choroidal blood vessels remaining apparent in the macula, far peripheral retina, and near the optic disc. At this stage, the sclera becomes visible during fundus examination in areas where the choroidal and RPE atrophy is complete. Managing Choroideremia involves regular ophthalmologic examinations to monitor the condition's progression or the emergence of cataracts. Additionally, individuals are advised to use UV-blocking sunglasses to protect their eyes. Unfortunately, there is currently no available treatment for Choroideremia.

·       Choroideremia is considered a rare disorder, with an estimated prevalence of 1 in 50,000 to 100,000 people.

 

Thelansis’s “Choroideremia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Choroideremia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Choroideremia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Choroideremia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Choroideremia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Choroideremia, Choroideremia market outlook, Choroideremia competitive landscape, Choroideremia market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)